Message
Bio-Pharmaceutical Hub (Updated)
Value
PROJECT ID
172025212
SECTOR
Healthcare & Pharmaceuticals
PROJECT PHASE
Initiation & Feasibility
LOCATION
Alatau, Kazakhstan
START DATE
11/1/2025
END DATE
11/1/2028
INVESTMENT VALUE
$ 200 M
Active
Verified
Updated: 2 Days ago
Publication: May 8, 2026
Project Description
The Khan Tengri Biopharma project involves the construction of a modern full-cycle biopharmaceutical manufacturing complex in the Alatau Special Economic Zone in Kazakhstan. The facility is designed to produce a wide range of pharmaceutical products using advanced manufacturing t... Read more
Involved Companies & Contacts
Involved Companies & Contacts
Company:
1. party1CompanyNameText
Role:
2. party1RoleRepeater
Address:
3. party1CompanyAddressText
Phone:
4. party1CompanyPhoneText
Email:
5. party1CompanyEmailText
Other links:
7. party1CompanyWebsiteText
Website:
6. party1CompanyWebsiteText
Key Contacts 1
Name:
party1Contact1NameText
Position:
party1Contact1PositionText
Phone:
party1Contact1PhoneText
Email:
party1Contact1EmailText
Links:
party1Contact1LinkText
Key Contacts 2
Name:
party1Contact2NameText
Position:
party1Contact2PositionText
Phone:
party1Contact2PhoneText
Email:
party1Contact2EmailText
Links:
party1Contact2LinkText
PARTY 1 - Involved Companies & Contacts
Field | Value |
|---|---|
Company | ░░░░░░░░░░░░░░░░░░░░░░░ |
Role | ░░░░░░░░░░░░░░░░░░░░░░░ |
Address | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Phone | ░░░░░░░░░░░░░░ |
Email | ░░░░░░░░░░░░░░░ |
Website | ░░░░░░░░░░░░░░░░░░░░░░░ |
Other Links | NA |
companyTable
Field | Value |
|---|---|
Name | ░░░░░░░░░░░░░░ |
Position | ░░░░░░░░░░░░░░ |
Phone | NA |
Email | ░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Links | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
contact1Table
contact2Table
Field | Value |
|---|---|
Name | NA |
Position | NA |
Phone | NA |
Email | NA |
Links | NA |
PARTY 2 - Involved Companies & Contacts
Field | Value |
|---|---|
Company | ░░░░░░░░░░░ |
Role | ░░░░░░░░░░░░░░░░░░░░░░░ |
Address | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Phone | ░░░░░░░░░░░░░░░░░░░░░░░ |
Email | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Website | ░░░░░░░░░░░░░░░░░░░░░░░░ |
Other Links | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
companyTable
Field | Value |
|---|---|
Name | ░░░░░░░░░░░░░ |
Position | ░░░░░░░░░░░░░░ |
Phone | NA |
Email | NA |
Links | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
contact1Table
contact2Table
Field | Value |
|---|---|
Name | ░░░░░░░░░░░░░░ |
Position | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Phone | NA |
Email | ░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Links | ░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ |
Company:
Value
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Value
Links:
Value
Phone:
Value
Value
Email:
Position:
Value
Name:
Value
Links:
Value
Email:
Company:
VALUE
Phone:
Value
Email:
Value
Address:
Value
Role:
Value
Website:
Value
Other links:
Value
Phone:
Value
Value
Email:
Name:
Value
Position:
Value
Links:
Value
Key Contacts
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Company:
VALUE
Email:
Value
Phone:
Value
Address:
Value
Other links:
Value
Role:
Value
Website:
Value
Phone:
Value
Email:
Value
Name:
Value
Position:
Value
Links:
Value
Key Contacts
Phone:
Value
Email:
Value
Name:
Value
Position:
Value
Links:
Value
Company:
VALUE
Phone:
Value
Email:
Value
Address:
Value
Website:
Value
Role:
Value
Other links:
Value
Value
Phone:
Email:
Value
Name:
Value
Position:
Value
Links:
Value
Key Contacts
Phone:
Value
Email:
Value
Name:
Value
Position:
Value
Links:
Value
Other important details
Khan-Tengri Biopharma was incorporated on March 6, 2025, just a few months before it appeared on the agenda of the Investment Headquarters. Officially, the company is building a full-cycle biopharmaceutical complex in the Alatau free Economic Zone, but there is no information about its production facilities and completed projects. The State Revenue Committee evaluates the tax risk as average. The company is headed by Askar Karimullin, who previously held senior positions at the Samruk-Kazyna Fund and BTA Bank. Until April 21, 2025, Karimullin was the sole founder, after which TengriX Ltd., which he also headed, joined the company as a co-founder. Co-owners of TengriX Ltd. These are Khan Tengri Capital, R-Pharm JSC and Sima Ltd.
The project involves the conclusion of an investment agreement with the Government of Kazakhstan and its implementation within three years. The products will be supplied not only to the domestic market of Kazakhstan, but also for export.
The company has committed to reducing the cost of medicines for consumers by about 20% every three years, offsetting this through exports.
The project is planned to be implemented in the new city of Alatau, the site for which has already been allocated. This was announced by Nikolay Zemskov, director of R-Pharma, on the sidelines of KGIR-2025, the government's press service reports.
"We have created a joint venture that is awaiting the conclusion of an investment agreement with the Government of the Republic of Kazakhstan. The project was approved by the investment headquarters. We were given a plot of land in the most promising city of the future, Alatau," Nikolai Zemskov said.
Sources
Publication Date
4/8/2026